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Available online 30 September 2016Carbon nanotubes (CNTs) have long been regarded as promising carriers in biomedicine. Due to their high sur-
face area and unique needle-like structure, CNTs are uniquely equipped to carry therapeutic molecules across bi-
ological membranes and, therefore, have been widely researched for use in theranostic applications. The
attractive properties of the CNTs entice also their use in the brain environment. Cutting edge brain-speciﬁc ther-
apies, capable of circumventing the physical and biochemical blockage of the blood-brain barrier, could be a pre-
cious tool to tackle brain disorders. With an increasing number of applications and expanding production, the
effects of direct and indirect exposure to CNTs on cellular and molecular levels and more globally the general
health, must be carefully assessed and limited.
In this chapter, we review the most recent trends on the development and application of CNT-based nanotech-
nologies, with a particular focus on the carrier properties, cell internalisation and processing, and mechanisms
involved in cell toxicity. Novel approaches for CNT-based systemic therapeutic brain delivery following intrave-
nous administration are also reviewed. Moreover, we highlight fundamental questions that should be addressed
in future research involving CNTs, aiming at achieving its safe introduction into the clinics.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Carbon nanotubes (CNTs) are deﬁned as cylindrical nanomaterials
composed of a continuous, unbroken hexagonal mesh of carbon
atoms. The ﬁrst observation of CNTs by electron microscopy, credited
to Iijima in 1991, opened a plethora of applications for this material
[1]. This included not only high-strength composites, energy storage,
and ﬁeld emission device, but also the use of CNTs for biomedical appli-
cations [2]. In particular, CNT ability to cross efﬁciently cell membranes
and carry a large amount of molecules has encouraged the design of
nanotube-based delivery systems [3,4].
The concept of drug delivery was probably introduced by Paul Ehr-
lich, in 1897, when he theoreticized the use of “zauberkugeln” (in En-
glish “magic bullets”) intending to improve the efﬁcacy of available
therapeutics [5]. Long after this statement, delivery of therapeutic and
imaging agents into speciﬁc organs or tissues has remained a promising
approach to modulate the pharmacokinetics and bioavailability of ther-
apeutics, and provide controlled release kinetics at a target site. Numer-
ous materials with sizes between 10 and 1000 nm have been
investigated, including liposomes, dendrimers, nanoemulsions, nano-
particles, quantum dots and CNTs. With their needle-like shape, CNTs
display singular physico-chemical properties. Their large surface area,
ranging from 50 to 1315 m2/g, allows the conjugation with extensive
amount of therapeutic and imaging molecules [6–8]. Moreover, the
high CNT length-to-diameter ratio enables them to efﬁciently penetrate
biological membranes and accumulate into intracellular compartments
[9]. Consequently, attachment of molecules to CNTs helps overcoming
several administration problems, including insolubility, poor
biodistribution and inability of therapeutic or diagnostic molecules to
cross cellular barriers [3].
Despite their undeniable potential, concerns have emerged regard-
ing the toxicity of CNTs, as various reports showed that pristine nano-
tubes could induce biological damage [10]. Excessive nanotube length,
the presence of impurities from the synthesis process and the introduc-
tion of carboxylic groups at the CNT surface could trigger unattended
and detrimental cellular responses [11]. Such parameters must there-
fore be thoroughly controlled and characterised to design safe and bio-
compatible nanotubes applicable as delivery systems. The post-
synthesis surface modiﬁcation of nanotubes with hydrophilic mole-
cules, named functionalisation, has been reported as an efﬁcient ap-
proach to enhance their water dispersibility and reduce their toxicity
[12,13]. This can be performed by covalently attaching moieties at the
surface of CNTs or by non-covalent interactions between nanotube sur-
face and hydrophobic/aromatic regions of amphiphilic molecules [14].
To tailor nanotube function, therapeutic molecules or imaging
probes can be added to functionalised CNT (ƒ-CNT) side-walls [4]. By
taking advantage of their inner cavity, ƒ-CNTs can also be ﬁlled to keep
the surface available for further modiﬁcations [15]. Contrast agents
can be combined to nanotubes to generate CNT-based hybridswith clin-
ical imaging capabilities [16]. If such hybrids display desirable targeting
capabilities, they become versatile imaging tools for diagnosticapplications [17,18]. CNT hybrids can also help tracking administrated
nanocarriers to assess in real-time their spatial distribution and there-
foremeasure their biodistribution proﬁle [19]. Themajormedical imag-
ing techniques, namely ultrasound, nuclear and magnetic resonance
imaging (MRI), display limitation in terms of sensitivity or image reso-
lution. To improve this, the combination of synergistic imaging modali-
ties in a single carrier, such as CNTs, could be particularly valuable [20].
Beyond the promising properties of CNT-based hybrids for multi-imag-
ing capabilities, their dimensions need to be optimised in order to con-
trol their intrinsic imaging properties, improve their accumulation in
target cells and enhance their biocompatibility proﬁle. This dimension
reﬁnement is essential to demonstrate the potential of CNT-based hy-
brids and conﬁrm their safety before conducting clinical studies.
A wide range of studies have also reported on the development of
carbon nanotubes for brain delivery,with results showing that adequate
functionalisation is essential to produce biocompatible CNTs capable of
local or systemic delivery of therapeutics to brain cells [21].
In this review, a description of the physico-chemical properties and
surface modiﬁcation of CNTs needed for delivery will be presented.
Moreover, the interaction between CNTs and mammalian cells will
then be described, followed by a summary of their toxicity. Finally, we
will look into the most recent advances involving CNT-mediated sys-
temic brain delivery and in situ CNT biodegradation.2. Physico-chemical properties and surfacemodiﬁcation of CNTs for
biomedical applications
2.1. Synthesis, classiﬁcation and properties
Carbon nanotubes can be generated by electric arc discharge and
laser ablation using vaporisation of graphite target [22,23]. Alternative-
ly, they are synthesised by chemical vapour deposition which rely on
the passage of carbon-containing vapours in a furnace containing
metal catalysts [24]. CNTs can be classiﬁed as single-walled (SWNT) or
multi-walled (MWNT) nanotubes, in accordance with the number of
layers that compose a single nanotube (Fig. 1).
SWNT and MWNT exhibit a diameter of 0.4–2 nm and 10–100 nm,
respectively [26]. Both types are utilised as delivery systems and display
large aspect ratios with lengths ranging from 50 nm to several microns.
The length and diameter can be tuned by controlling the production
conditions, but the design of CNT-based delivery systems requires fur-
ther post-synthesis shortening procedures to increase their biocompat-
ibility and bioavailability [10,19]. A reduction in the CNT length to
diameter ratio can be achieved by strong acid treatment,
ultrasonication, steam-puriﬁcation and mechanical methods [27–29].
The uniquephysicochemical properties of CNTs, namely high surface
area and length-to-diameter ratio, optimal electrical conductivity, and
thermo-chemical stability, make them particularly attractive for bio-
medical applications [30]. However, pristine CNTs must be
functionalised to improve their hydrophilicity and biocompatibility.
Fig. 1. Schematic representation of single-walled (SWNT) and multi-walled (MWNT) CNTs. Single and multi-walled CNTs have similar structures but different diameters. The ﬁgure was
redrawn and modiﬁed from [25] and [26].
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The delocalised aromatic system of nanotube layers makes them ag-
gregate in bundles and results in their poor dispersibility in physiologi-
cal aqueous environment [31]. The large surface area of CNTs enables
non-covalent or covalent conjugation of hydrophilic molecules to en-
hance their dispersibility [13]. The non-covalent modiﬁcation consists
in the physical adsorption of amphiphilic surfactant molecules onto
the surface of the CNTs by Van der Waals interaction, π-π stacking or
electrostatic interaction [32–34]. The main advantages of this approach
are the preservation of the intrinsic optical properties of CNTs and the
simplicity of the functionalisation procedure [30]. However, the interac-
tion after coating should be limitedly affected by the presence of salt to
maintain the stability of the complex in a physiological environment.
Biocompatible polymers (e.g. Pluronic® F-127, polyethylene glycol
(PEG)) [35,36], gum arabic [37], single-stranded DNA (ssDNA) [38]
and proteins (e.g. bovine serum albumin, BSA) [39,40] were reported
to increase the dispersibility of CNTs.
2.3. Covalent functionalisation
Covalent CNT functionalisation relies on the chemical bonding of
functional groups to the wall of CNTs, and is also referred as chemical
functionalisation [41]. In contrast to the non-covalent approach, chem-
ical functionalisation leads to strong and stable chemical bonds grafted
onto the sp2 carbon framework of the tips and sidewall of CNTs [42]. The
functionalisation of CNT can be carried out by oxidation under strong
acidic conditions, which produces carboxylic acid groups and shorten-
ing of CNTs [43]. However, the introduction of carboxylic groups at the
surface of CNTs has been associated with cellular toxicity [28,44]. Fur-
ther reactions can conjugate carboxylic acid groups to an amine or alco-
hol groups to obtain amide or ester linkage, respectively [13]. In
addition to oxidation, another common chemical reaction is the 1,3-di-
polar cyclo-addition using the condensation of an amino acid and an al-
dehyde [45].
Both covalent and non-covalent functionalisations have shown their
ability to increase the dispersibility of nanotubes in a physiological envi-
ronment, making them available to cross cell membranes and accumu-
late into intracellular compartments.
3. Uptake and cellular fate of functionalised CNTs (ƒ-CNTs) in cancer
cells and macrophages
Efﬁcient uptake properties of CNTs have encouraged their use as
drug delivery systems. After crossing the plasma membrane, theintracellular pathways of CNTs can lead to organelle accumulation
and/or nanotube elimination [46–50]. The characterisation of their
mechanisms of uptake and elimination remains of great interest to
shape the delivery properties of CNTs and ensure their bio-
clearance.3.1. Passive versus active mechanism
A leading study by Pantarroto and collaborators demonstrated that
the high aspect ratio of CNTs allowed them to efﬁciently cross cellular
membranes [9]. Subsequently, a dual mechanism of uptake into mam-
malian cells has been described [51]: CNTs were shown to use either
an endocytic pathway or the passive diffusion to penetrate through cel-
lular membranes (Fig. 2). In the endocytic mechanism, CNTs are
internalised inside vesicles, named endosomes, before being direct-
ed to the lysosomes localised in the perinuclear compartment [52].
The energy-dependent uptake of nanotubes was described as pre-
dominantly clathrin-dependent for both SWNT and MWNT [53,54].
Kang and colleagues showed that SWNT/doxorubicin complexes,
conjugated via hydrophobic π stacking, were internalised using the
endocytic pathway and accumulated into the perinuclear lysosomal
compartment of endothelial progenitor cells [49]. While SWNT
remained entrapped into lysosomes, DOX detached in the acidic ly-
sosomal environment due to the pH-dependent π-π stacking inter-
action, diffused into the cytoplasm and reached the nuclear
compartment to induce cell killing.
In contrast, the passive diffusion of CNTs, also called needle-like pen-
etration, results in the simple diffusion of CNTs through the cellular
membranewithout need of energy consumption [9,55]. Following com-
putational and electron microscopy studies, the passive diffusion of
ƒ-CNTs through the phospholipid bilayer membrane, has been broken
down in three steps: i) landing and ﬂoating of the ƒ-CNTs on the mem-
brane surface; ii) penetration of the lipid head groups; and iii) sliding
through the lipid tails (Fig. 2) [56,57].
A model explaining the differential mechanism of uptake between
active and passive mechanisms has been proposed by Yan and co-
workers [51]. Accordingly, CNT clusters would be internalised by an
endocytic mechanism, whereas individualised nanotubes would enter
the cell by membrane diffusion (Fig. 2).
Interestingly, despite the signiﬁcant effort dedicated to the char-
acterisation of CNT internalisation pathways, there is no report sug-
gesting that passive transport is preferred to endocytosis for drug
delivery applications. However, one could indicate that both path-
ways support the versatile capabilities of CNTs to cross biological
membranes.
Fig. 2. Uptake and cellular fate of ƒ-CNTs in mammalian cells. The bundled MWNTs bind to cellular membranes and are then internalised into cells by endocytosis. In the endosomes,
bundles release single MWNT, which penetrate through endosomal membranes and enter the cytosol. Alternatively, short and individualised CNTs (i) land on the surface of the
plasma membrane, (ii) penetrate the lipid head groups and ﬁnally (iii) slide through the lipid tails to passively diffuse through the cell membrane. Both residual bundled MWNT in
endosomes and free MWNT in the cytosol are recruited into lysosomes. CNTs can be excreted by exocytosis (not shown) or in autophagic microvesicles in case of cellular stress.
Another exit mechanism has been reported in polynuclear neutrophils and macrophages where nanotubes are digested enzymatically. CNTs are also able to enter organelles and the
nucleus. The ﬁgure was redrawn and modiﬁed from [51].
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The use of CNTs for drug delivery entails their capture by macro-
phages, which participate in homeostasis and physiological defence
mechanisms [58–60]. These cells are especially involved in the removal
of external materials by phagocytosis, a cell endocytic pathway similar
to endocytosis but involving the uptake of large particles (∼1 μm).
Both endocytosis and phagocytosis are energy-dependent mechanisms
that are impeded at low temperature [53]. Phagocytic cells take up CNTs
mainly through phagocytosis but the blockade of this energy-depen-
dent pathway still allows the uptake of CNTs by passive diffusion [61].
SWNTs coated with phospholipid-polyethylene glycol (PL-PEG) were
found to cross the cell membrane of non-phagocytic cells (ASTC-a-1,
COS7, MCF7, EVC304) by passive diffusion and accumulate into mito-
chondria, whereas in macrophages (RAW264.7), CNTs accumulated in
lysosomes following a phagocytic mechanism [62]. These results sug-
gest that the internalisation mechanism of nanotubes was dependent
not only on the properties of CNTs but also on the phagocytic nature
of cells. Within the same population of phagocytic cells (human mono-
cyte-derived macrophages), a study intended to establish a differential
uptake of ﬂuorescently labelled nanotubes as function of their length
[63]. Constructs above 400 nm in length were mainly localised in
endocytic vesicular structures, while the ﬂuorescent signal from shorter
CNTs was more diffuse, supporting their extra-vesicular localisation in
cell cytoplasm.
Overall, these results suggest that shortening of CNTs enhances their
passive diffusion uptake mechanism, even in phagocytic cells.3.3. Cellular fate of CNTs
Following their passage through cellular membranes, CNTs were re-
ported to accumulate in various subcellular compartments, such as the
cell cytosol [61], endosomes [54,64], the perinuclear region [65], mito-
chondria [62,66] or the nucleus [51], according to their physicochemical
properties and functionalisation. Exocytosis and biodegradation of CNTs
have also been reported as possible cell eliminationmechanisms for thismaterial [46,47,50]. The description of such outcomes is crucial to con-
ﬁrm the potential of CNT bio-elimination, ultimately lowering the risk
of CNT toxicity.
3.3.1. Exocytosis
Taking advantage of the intrinsic CNT photoluminescence proper-
ties, SWNTs were tracked by Jin and colleagues in real-time using single
particle tracking, and showed similar endocytosis and exocytosis rate
(Fig. 2). [46,47]. Using Raman spectroscopy mapping, Neves and col-
leagues found that oxidised and RNA-wrapped double-walled CNTs
(DWNTs) accumulated in cells over 3 h before being progressively re-
leased out of the cells over a 24 h period [67]. It recently emerged that
the process of exocytosis could also be induced under stress conditions.
Naive human monocyte macrophages and endothelial cells exposed to
stress were able to release microvesicles containing CNTs [68]. This
mechanism could eliminate exogenous and toxic carbonmaterial by in-
ducing the formation of autophagic microvesicles [69].
3.3.2. Enzymatic degradation
The enzyme degradation of CNTs was reported as a possible
mechanism by which cells eliminate this material (Fig. 2). Studies by
Allen and collaborators provided evidence of the degradation of
oxidised SWNTs through enzymatic catalysis in abiotic conditions [70,
71]. Following the incubation of carboxylated SWNT with horseradish
peroxidase in low H2O2 concentrations (40–80 μM), a combination of
techniques including transmission electron microscopy (TEM), Raman
and ultraviolet-visible-near-infrared (UV-NIR) spectroscopy, and
showed that digested CNTs displayed reduced absorbance, dramatic
length shortening and disappearance of their discriminating G- and D-
bands. It was later proposed that the presence of carboxylic group and
defects at the surface of CNTs are a prerequisite to trigger the interaction
with the oxidative agent and that nanotube degradationwas function of
the defect density [72]. Using similar techniques, it was demonstrated
that in vitro exposure of SWNTs to neutrophils followed by enzymatic
digestion with myeloperoxidase (MPO) promoted alterations in CNT
structure [73,74]. These ﬁndings were supported by in vivo studies
using TEM, Raman spectroscopy and photoacoustic imaging, which
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ministration in mice [48,75]. Using TEM and Raman spectroscopy, our
group also found evidence of SWNT degradation in mouse brain after
stereotactic injection [76]. In a recent study, the amount of CO2 released
from the enzymatic digestion of nanotubes in contact with horseradish
peroxidase was measured, with a CNT degradation rate of ~0.002% per
day being reported, which corresponds to a half-life of ~80 years [77].
While studies conﬁrm that CNTs can be enzymatically degraded, the
notion of degradation is still broadly employed and future reports must
provide qualitative and quantitative data regarding the formation of by-
products induced by CNT enzymatic degradation, especially for in vivo
investigations.4. Biocompatibility of CNTs
The toxicity of CNTs has been widely reported and is of major con-
cern for human use [78]. It is accepted that CNTs are heterogeneousma-
terial with certain physico-chemical properties that can promote
deleterious biological responses [11]. Therefore, the use of CNTs, applied
to the drug delivery ﬁeld, requires the design of materials with en-
hanced biocompatibility properties to ensure the safe translation of
this material into clinical use.4.1. Main properties of CNTs inﬂuencing toxicity
CNTs exhibit heterogeneous purity, length, type of functionalisation
and surface interaction with plasma proteins that can affect their cellu-
lar toxicity. CNT toxicity mechanisms have been mostly explored by
measuring cell viability, cell inﬂammation and the production of reac-
tive oxygen species (ROS).
The concept of cellular toxicity can be described using the Hierarchi-
cal Oxidative StressModel associating the cell toxicitymechanismswith
the intracellular levels of ROS [79] (Fig. 3). At low concentrations, ROS
can be neutralised by anti-oxidants - e.g. glutathione (GSH), and detox-
iﬁcation enzymes. When the antioxidant defence is overwhelmed, fur-
ther damages occur such as lipid peroxidation, change in cell
morphology and genotoxicity [80,81]. Excessive ROS production initi-
ates an inﬂammatory response through the release of cytokines and
chemokines [80,82]. Finally, further ROS production induces the release
of apoptotic factors leading to cell death [83]. Themeasurement of such
end points relies more frequently on the quantiﬁcation of cell metabo-
lism, DNA content,membrane disruption or cellular apoptosis induction
[28,84].
In vitro toxicity studies comparing physico-chemical properties of
CNTs are summarised and classiﬁed in Table 1.
The main factors involved in CNT toxicity are reported hereafter.Fig. 3. Hierarchical Oxidative Stress Model. This model associates the cell toxicity
mechanisms with the intracellular levels of ROS. The ﬁgure was re-drawn and modiﬁed
from [85].4.1.1. Impurities
Catalyst remnants from the CNT synthesis, such as nickel (Ni), cobalt
(Co), iron (Fe) and molybdenum (Mo), and amorphous carbon, local-
ised at the surface of nanotubes or entrapped within the CNTs, can
lead to oxidative stress, anti-oxidant depletion and a reduction in cell vi-
ability [86,101,102]. Several methods can be used to reduce the pres-
ence of impurities including high-temperature annealing, acidic
treatment by reﬂux or steam-puriﬁcation [101,103,104]. It has been
demonstrated that CNTs free of catalyst metals and graphitic contami-
nants are unlikely to result in any inﬂammatory response or impair-
ment of phagocytosis [105].
4.1.2. Dimensions
CNT length has been shown to greatly inﬂuence CNT toxicity. Ex-
tremely long CNTs (10–20 μm) displayed asbestos-like behaviour and
long bioretention in peritoneal mesothelium [11]. When macrophages
attempted to engulf long CNTs displaying larger dimension than the ac-
tual cell, it resulted in frustrated phagocytosis leading to formation of
granuloma [106]. Such lengths are impractical for drug delivery and
the shortening of CNTs has emerged as a logical requirement for bio-
medical applications. Following the same mechanism, MWNT of 2.4–
10 μm length, coated with Pluronic® F-127, exerted higher toxicity
than shorter materials (0.4–1.4 μm) in a murine macrophage cell line,
while shorter CNTs led to higher inﬂammatory response [93]. This op-
posite effect of CNT length on cell viability and inﬂammation suggested
that the Hierarchical Oxidative Stress Model could not always be ap-
plied to characterise the toxicity of CNTs. Other studies reported dispar-
ities between the impact of CNTs on cell viability and inﬂammation/
oxidative responses [97,101,107,108]. The effect of nanotube diameter
on cellular toxicity was described only in few studies and contradictory
results were reported, thus limiting any statement about the inﬂuence
of such parameter [109,110].
4.1.3. Defects
Defects at the surface of nanotubes may be topological (e.g. ring
shapes other than hexagon), sp3 hybridised carbon atoms, incomplete
bonding defects, doping with elements other than carbon, as well as
various functionalities at the surface [111]. Studies by Fenoglio and
Muller established that the presence of defects at the surface of CNTs
triggered acute pulmonary toxicity and genotoxicity [84,112]. It was
later reported that the shortening of CNTs by sample ultra-sonication
using concentrated acid solution produced defects at the surface of the
nanotubes, which were correlated with enhanced pro-inﬂammatory
and pro-oxidative response [28]. Such report demonstrated that the
shortening process could be associated with the formation of defects
leading to inﬂammation and cytotoxicity.
Due to the heterogeneity of CNTs and the lack of data about CNT sur-
face characterisation, the association between CNT toxicity and their
physico-chemical properties can be puzzling. For example, Cheng and
collaborators found that short MWNT (0.2 ± 0.1 μm) altered the devel-
opment of zebraﬁsh embryo, while longMWNT (0.8± 0.5 μm) showed
reduced embryo-toxicity [113]. Although the authors concluded that
nanotube length inﬂuenced the toxicity on embryos, the formation of
defects at the surface of nanotubes induced by prolonged ultra-sonica-
tion in concentrated acid could just as well be responsible for the toxic-
ity measured [113].
4.1.4. Functionalisation
Efﬁcient dispersion resulting in individualised CNTs must be
achieved for drug delivery applications in order to reduce the formation
of CNT aggregates and increase their biodisponibility [19]. The type and
degree of functionalisation tend to inﬂuence CNT toxicity. Surface func-
tionalisation of nanotubes with carboxylic groups, using acid treatment,
showed increased defect formation at the surface of CNTs adsorbing cat-
alyst particles and generating free radicals [114]. Humanneuroblastoma
cells exposed to different concentrations of oxidised MWNT showed
Table 1
In vitro comparative studies of ƒ-CNTs toxicity.
List of abbreviations in this table: AM: alveolarmacrophages; ATII: primary human alveolar type-II epithelial cells; ATP: adenosine triphosphate; BAL: bronchus-alveolar lavage ﬂuid; BCA:
bicinchoninic acid assay; CHO: Chinese hamster ovary cells; CXCL-2: chemokine CX motif ligand 2; DPPC: dipalmitoylphosphatidylcholine; EthD-1: ethidium homodimer-1; gCNTs:
grounded carbon nanotubes; GSH: glutathione; hprt: hypoxanthine-guanine phosphoribosyltransferase; LDH: lactate dehydrogenase; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTT: 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide; NLRP3: nucleotide-binding domain leucine-rich re-
peat and pyrin domain containing receptor 3; NO: nitric oxide; NT1: uncoated carbon nanotubes; NT2: carbon nanotubes coated with acid based polymer; NT3: carbon nanotubes coated
with polystyrene-based polymer; RNS: reactive nitrogen species; SWNT-PEG: single-walled carbon nanotubes functionalisedwith polyethylene glycol; TUNEL: terminal deoxynucleotidyl
transferase dUTP nick end labelling; TT1: human alveolar type-I-like epithelial cells; XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide; WST-1: 4-[3-(4-
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate; ➚: increase; ➘: decrease.
CNT type and properties Functionalisation Cell model Viability/proliferation/morphology ROS/inﬂammation/genotoxicity Reference
Catalyst impurities SWNT (Fe: 0.23
vs 26 wt.%)
Serum coated Mouse
macrophages
(RAW 264.7)
− 26 wt.% Fe: ➚ NO; ➚ superoxide
radicals; ➚ GSH content
[86]
MWNT (Fe: 4.2
vs 12.0 wt.%)
Pluronic® F-108
coated
Rat
pheochromocytoma
(PC12) cells
12.0 wt.% Fe: ➘ cell viability
(CCK-8 assay), ➚ cytoskeleton
disruption, ➘ neurite outgrowth
12.0 wt.% Fe: slight ➚ of
intracellular ROS
[87]
MWNT (Fe: 0.05
vs 0.5 wt.%)
Serum coated Murine alveolar
macrophages
(MH-S)
0.5 wt.% Fe: ➚ of LDH release 0.5 wt.% Fe: ➘ GST;
➚ lipid peroxidation
[88]
MWNT (Ni: 2.54–5.47
wt.%)
Serum coated Primary alveolar
macrophages
Ni-rich CNTs: ➘ cell viability (MTS
assay)
Ni-rich nanotubes: ➚
pro-inﬂammatory cytokines
(IL-1β &
IL-18); ➚ NLRP3 activation
[89]
MWNT (Fe: 0.08 vs 4.24
wt.%)
Gum arabic-coated Human alveolar
epithelial cells
(A549)
No signiﬁcant difference on cell
viability (LDH, MTT and XTT
assays)
− [90]
CNT length SWNT (length: 0.5–2 μm
vs 5–30 μm)
Polyvinylpyrrolidone
coated
Dynamic cell
culture system of
human alveolar
epithelial cells
(A549)
Long CNTs: ➘ cell proliferation
(BCA assay)
Long CNTs: ➚
pro-inﬂammatory cytokines
(IL-8); ➚ ROS production
[91]
MWNT (average length:
0.6 μm vs 3 μm vs
20 μm)
Serum coated Human alveolar
type-I-like
epithelial cells
(TT1)
Primary human
alveolar type-II
epithelial cells
(ATII)
Alveolar
macrophages (AM)
Long CNTs: ➚ cell viability (MTT
and LDH assay) in epithelial cells
(TT1, ATII) and ➘ cell viability in
AM
Long CNTs: ➚
pro-inﬂammatory response
(IL-6, IL-8 and MCP-1) in
epithelial cells (TT1, ATII) but ➘
pro-inﬂammatory effect in AM
[92]
MWNT (length:
0.4–1.4 μm vs
2.4–10 μm)
Pluronic® F-127
coated
Murine
macrophages
(RAW264.7)
Human breast
cancer cells
(MCF-7)
Long CNTs: ➘ cell viability
(CellTiter-Blue assay and trypan
blue counting)
Long CNTs: ➘
pro-inﬂammatory response
(TNF-α and IL-12); ➚ ROS
production
[93]
MWNT (average length:
150 nm vs 20 μm)
Dispersion in DPPC
solution
Salmonella
typhimurium
Escherichia coli
Chinese hamster
ovary cells (CHO)
− Both CNT lengths did not affect
genotoxicity (Ames test, in vitro
chromosome aberration assay)
[94]
SWNT (length:
400–800 nm vs 1–3 μm
vs 5–30 μm)
Serum coated Human bronchial
epithelial cells
(BEAS-2B) Human
lymphoblastoid B
cells (MCL-5)
CNTs with middle-range length
(1–3 μm) ➘ cell viability
(cytokinesis-blocked
micronucleus assay)
CNTs with middle-range length
(1–3 μm) ➚ hprt forward
mutation assay and ➚ ROS
production
[95]
MWNT
(average length: 950 nm
vs 250 nm)
Carboxylation vs
amination
Whole human
blood
Long aminated CNTs: ➘ platelet
viability (CD61 labelling)
− [96]
Presence of defects MWNT Grounded CNTs
(gCNT) with structural
defects vs heated CNTs
with few oxygen
functionalities
Oxygen
functionalities
introduced by
grinding
Cells from
broncho-alveolar
lavage ﬂuid (BAL)
gCNTs ➘ cell viability (LDH and
protein content, macrophages and
neutrophils counting in BAL)
gCNTs ➚ pro-inﬂammatory
response (IL1-β, TNF-α)
gCNTs ➚ genotoxicity (➚
micronucleated binucleated
cells)
[84]
MWNT CNTs of 9.5 μm vs
shortened CNTs of
4.8 μmwith high
content of structural
defects
Short CNTs: oxygen
functionalities
introduced by acid
treatment and
ultra-sonication
Mouse
macrophages (RAW
264.7)
No difference between short and
long CNTs in terms of cell viability
(WST-1)
Short CNTs: ➚
pro-inﬂammatory response
(TNF-α and CXCL-2) and
➚ pro-oxidative response
[28]
(continued on next page)
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Table 1 (continued)
CNT type and properties Functionalisation Cell model Viability/proliferation/morphology ROS/inﬂammation/genotoxicity Reference
CNT
functionalisation
MWNT Uncoated CNTs
(NT1) vs CNTs coated
with acid based polymer
(NT2) or
polystyrene-based
polymer (NT3)
Polymer coated Mouse
macrophages (RAW
264.7)
Cell viability (MTT) was higher in
NT1 N NT2 N NT3
Inﬂammation (CXCL-2) and
oxidative stress (HO-1) were
higher in NT3 N NT2 N NT1
[97]
MWNT Pristine CNTs vs
oxidised CNTs vs amino
functionalised CNTs
Oxidised CNTs or
amino-functionalised
CNTs with
ethylene-diamine
Mouse
macrophages (RAW
264.7)
All CNTs ➘ proliferation
(intracellular ATP) and viability
(extracellular ATP). Oxidised CNTs
➚ anti-proliferative effect
– [44]
MWNT
Oxidised CNTs at
increased density
Oxidation of CNTs for
1 to 8 h in acid
Mouse
macrophages
(RAW264.7)
Increased density of carboxylic
groups ➚ cell death (MTT) and
➚ cell apoptosis (TUNEL) in a
concentration manner
High density of carboxylic
groups:
➚ RNS in a concentration
manner
[98]
SWNT Covalent
functionalised CNTs vs
non-covalently
functionalised CNTs
SWNT-phenyl-SO3Na
(increased density
ratio) vs Pluronic®
F-108 coated SWNT
Human dermal
ﬁbroblasts
Pluronic® coated CNTs: ➚
cytotoxicity (calcein AM &
EthD-1, MTT); SWNTs degree of
functionalization ➘ cytotoxicity
− [99]
SWNT
Pristine SWNT vs SWNTs
functionalized with
polyethylene glycol
(SWNT-PEG)
Pristine SWNT vs
SWNT-PEG
Neuronal PC12 cells SWNT-PEG: ➘ cytotoxicity (MTT,
XTT, LDH); pristine SWNTs
induced spindle shape
morphology and SWNT-PEG
inhibited dendrite growth
Compared to pristine SWNTs,
SWNT-PEG ➘ ROS generation
and ➚ GSH level; SWNT-PEG ➘
gene expression associated to
cytotoxicity
[100]
MWNT
Amidated CNTs vs
aminated CNTs
Oxidation +
amidation vs
1,3-dipolar
cycloaddition
reaction
Peritoneal
macrophages
Lymphocytes B & T
Both CNT types did not affect cell
viability
Amidated CNTs ➚ inﬂammation
(IL-6, TNF-α) & ➘ LPS
restimulation (IL-6, TNF-α)
[12]
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cytes incubated with CNTs functionalised by 1,3-dipolar cycloaddition
— forming aminated nanotubes — did not increase the apoptotic pro-
portion of immune cells and preserved their inﬂammatory functionality
bymaintaining their interleukin secretion following the activation by li-
popolysaccharides (LPS) [12].
4.1.5. Protein binding
Protein binding to the surface of nanotubes occurs in a physiological
environment, such as the blood circulation system, but can also be used
as a strategy for CNT dispersion. The compact and multi-layer form of
bovine ﬁbrinogen (BFG) proteins was shown to reduce the toxicity of
CNTs proportionally to the degree of adsorption onto the surface of
nanotubes [115]. In contrast, Dutta and colleagues showed that
MWNT dispersed in serum bovine albumin induced pulmonary ﬁbrosis
[116]. By coating the same material with Pluronic® F-108, the amphi-
philic polymer was able to protect the lysosomal membrane from CNT
damage and abolish the formation of pulmonary ﬁbrosis [116].
4.2. Inﬂuence of cell model on CNT toxicity
Recent studies have highlighted that the toxicity of nanotubes is
dependent not only on their physico-chemical properties but also on
the cellular model used for toxicity assessment. In a study by Foldbjerg
and colleagues, epithelial cancer cells (A549), human monocyte-de-
rived macrophages (THP-1) and mouse macrophages (J774) were
exposed to SWNT dispersed in BSA. Incubation at 10 μg/ml led to reduc-
tion in cell viability, necrosis, reduction of phagocytic ability, increased
ROS levels and cytokine release in J774 cells, while A549 and THP-1
cells treated in the same conditions were not affected [117]. As J774
cells exhibited the highest phagocytic properties, the authors suggested
that the toxicity of SWNT was mostly dependent on the uptake capaci-
ties of the cellularmodel used. However, the lack of inclusion of primary
cells in this study could raise interrogations about thepertinence of suchresults in vivo. In a similar study, the toxicity proﬁle of pristineMWNTof
different lengths (0.6, 3 and 20 μm) was assessed in primary lung epi-
thelial cells (TT1), primary human alveolar type-II epithelial cells
(ATII) and primary lung alveolar macrophages (AM) [92]. Long MWNT
led to an increase in lactate dehydrogenase (LDH) release, cell viability
and cytokine secretion in AM cells, while shorter MWNT induced a
stronger response in epithelial cells. In an interesting study by Asghar
and colleagues, which focused on the toxicity of CNTs towards germline
cells, no signiﬁcant toxicity was found upon exposure of human sperm
samples to 1–25 μg/ml of carboxylated SWNTs, although higher concen-
trations resulted in a signiﬁcant increase in the production of reactive
superoxide species [118].
The different response of epithelial and macrophage-like primary
cells to CNTs highlights the need to select appropriate and relevant
models to test in vitro the toxicity of CNTs. In our opinion, epithelial
cells, macrophages and cells from the reticuloendothelial system should
be included in any studies aimed at assessing toxicity of CNT-based
nanocarriers.4.3. Mechanisms of cellular toxicity triggered by CNTs
Themechanisms of cellular toxicity induced bynanotubes have been
essentially described using pristine CNTs andweremostly related to the
production of oxygen radicals [50] (Fig. 4).
The induction of oxidative stress activates signalling pathways me-
diating inﬂammation and, ultimately, to cellular toxicity. Activation of
NF-κB or AP-1 transcription factors by CNTs has been directly involved
in upregulating genes involved for the release of cytokines such as IL-
1, IL-6 and TNF-α [50,119]. CNT-related oxidative stress could result in
oxidation of mitochondrial phospholipids and nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidation leading to inﬂammation and
apoptosis, but also positive outcomes such as CNT biodegradation in
neutrophils [71,120].
Fig. 4.Molecularmechanisms induced by CNT uptake. Schematic representation of themainmolecular and cellular responses associatedwith CNT internalisation by cells. Cell exposure to
CNTs could have negative effects, namely oxidative stresswhich can promote inﬂammation,mitochondrial oxidation and activation of apoptosis, blocking of ion channels leading to loss of
enzyme function and cytoskeleton interference imparting proliferation and migration. Effects reported as positive include activation of the complement system which promotes
phagocytosis and biodegradation of the CNTs.
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to the cellular accumulation of CNTs, such as the blocking of ion chan-
nels leading to loss of enzyme function, the interference with the cyto-
skeleton impacting proliferation, migration and phagocytosis, and the
potential induction of a tumourigenic response [121–123]. It was re-
ported that SWNT and DWNT could be responsible for activating the
classical and alternate pathways of the complement system [124]. This
was further associated with increased cellular inﬁltration and phagocy-
tosis, as well as reduced pro-inﬂammatory cytokine secretion, thus
supporting the beneﬁcial effect of complement activation triggered by
CNTs [125].
4.4. In vivo toxicity studies in non-brain tissues after intravenous adminis-
tration of CNTs
A majority of pre-clinical toxicological studies assessed the toxicity
of CNTs after pulmonary inhalation/exposure [10,106]. However, drug
delivery mediated by CNT carriers requires the study of their toxicity
following intravenous (i.v.) administration. In most reports, this evalu-
ation was done using histological analysis [58,126,127], blood cell
counting [128] and inﬂammation detection [126,127] in organs and
blood. A summary of the studies reporting the toxicity of ƒ-CNTs in mu-
rine models is presented in Table 2.
Dispersion was shown to be a key factor inﬂuencing CNT toxicolog-
ical effect. Indeed, puriﬁed pristineMWNT injected intravenously accu-
mulated mainly in the lungs as large aggregates, causing short-term
respiratory distress [58]. The intravenous injection of pristine MWNT
was also shown to form large CNT aggregates in liver and lungs and in-
duce inﬂammatory cell inﬁltration around the airways and blood ves-
sels in lung tissue [127]. In contrast, the i.v. injection of puriﬁed SWNT
dispersed in 1.0% wt Tween®-80 in mice resulted in limited organ tox-
icity, despite large accumulation in liver, lung and spleen organs [133].
An increase in GSH level in liver and lungs suggested the induction of
oxidative stress but the level of TNF-α in serum remained unchanged.
In another study, SWNT covalently or non-covalently functionalised
with PEG was injected i.v. in athymic mice. Histological and bloodanalysis of liver and spleen did not reveal any acute or chronic toxicity
up to four months post administration [128], thus suggesting that at-
tachment of appropriate functional groups at the surface of CNTs is a
critical parameter to enhance their biocompatibility.More recently, tox-
icity of chemically functionalisedMWNT to spleenwas evaluated over 2
months, with no functional or histological modiﬁcations detected [126].
However, MWNTs were shown to transfer from the red pulp to the
white pulp over time, suggesting the formation of a splenic adaptive
response.
Overall, the induction of in vivo inﬂammatory responses by ƒ-CNTs is
reduced but the persistence of suchmaterials inmajor organs (i.e. lungs,
liver and spleen) still requires further toxicological investigation. More-
over, there is currently no consensus about what animal models should
be used to assess the short and long-term impact of CNT exposure in bi-
ological tissues. It is important that clear guidelines are established by
the scientiﬁc community, so that the results and their interpretation/
comparison are not affected by the different testingmethods. Neverthe-
less, the results available to date suggest that i.v. injection of properly
functionalized CNTs is well-tolerated and their use as carriers for thera-
peutic and imaging applications can be justiﬁed.
5. CNTs as carriers for therapeutic brain delivery
The delivery of therapeutic molecules to the brain is severely re-
stricted by the presence of the blood-brain barrier (BBB), a complex net-
work comprising brain endothelial cells, astrocytes and other support
cells, that control the inﬂux and efﬂux of nutrients and other molecules
to the brain parenchyma. For this reason, treatment of complex neuro-
degenerative disorders and brain gliomas remains a challenge. When
particle size is not small enough to overcome the BBB size restriction
(i.e. b100 nm), nanoparticle-based brain-targeted therapeutic ap-
proaches have, thus far, taken advantage of the existing physiological
mechanisms of transport to improve brain delivery. Polymer- and
lipid-based nanoparticles are usually decorated with targeting moieties
to support receptor-mediated transcytosis across the BBB. The capacity
of CNTs to cross the BBB by both receptor- or adsorptive-mediated
Table 2
Representative in vivo studies of ƒ-MWNT and ƒ-SWNT injected IV in murine models
List of abbreviations in this table: ALP: alkaline phosphatase; d: diameter; ƒ-MWNT: functionalised MWNT; GPCRs: G protein-coupled receptors; inj.: injection; ISL: isoliquiritigenin; L:
length; NS: non-signiﬁcant; RES: reticulo-endothelial system; ➚: increase; ➘: decrease.
CNT type & functionalisation
Length (L)
and diameter
(d)
Murine model
administrated dose
treatment duration Biological measurements Histological & microscopic observations Reference
MWNTs - Functionalised with taurine
(ƒ-MWNT)
L: 269 ± 160
nm
d: 12.6 ± 3.2
nm
♀ Kunming mice
Dose:
60–100 mg/kg
Until 60 days
post-inj.
No alteration of RES phagocytic
activity and oxidative stress in the
spleen over 2 months
Spleen accumulation over 60 days without
histological damages
Relocation of ƒ-MWNTs from the red pulp
to the white pulp splenic region
[126]
- Non-dispersed (MWNT)
- Dispersed in Tween-80
(T-MWNT)
L: 0.5–5 μm
d: 40 nm
BALB/c mice
Dose:
100 μg/mouse
Until 28 days
post-inj.
Similar hepatic and renal functions
between MWNT and T-MWNT
groups at day 28
MWNT: in liver and lung and ➚
inﬂammatory cell inﬁltration
T-MWNT: in the liver only and cleared at
day 28
[127]
- Oxidised (s-MWNT)
- PEGylated (PEG-MWNT)
MWNTs
L: 125 ± 75
nm
d: 20 nm
Kunming mice
Dose:
100 μg/mouse
Until 3 days post
inj.
NS change in blood count and in
hepatic and renal functions
No accumulation observed histologically.
No evidence of inﬂammatory response
[129]
- Oxidised (o-MWNT)
- Dispersed in Tween-80
(T-MWNT)
L: 356 ± 185
nm
d: 10–20 nm
Kunming mice
Dose: 10 or 60
mg/kg
Until 60 days post
inj.
T-MWNT: induced oxidative stress
Both MWNTs altered hepatic
function and liver gene expression
(e.g. GPCRs, CYP450)
Both MWNTs induced hepatic damages
(T-MWNT N o-MWNT) at high dose
[130]
- Non-shortened and
non-functionalised
L: 15 ± 5 μm
d: 25 ± 5 nm
♂ C57BL/6 mice
Dose: 1 mg/kg
Until 7 day post-inj.
MWNTs induced T-cell activation in
the spleen
MWNT aggregated in the lungs with size ➘
over time
[131]
- Pristine (pMWNT)
- Amino-functionalised
(NH3-MWNT)
- DTPA functionalised
(DTPA-MWNT)
L: 0.5–2 μm
d: 20–30 nm
♀ BALB/c mice
Dose:
200–400 μg/mouse
Until 24 h post-inj.
All MWNTs: normal biological
functions;
NH3-MWNT ➘ total protein
pMWNTs ➘ ALP level without clear
physiological impact
All MWNTs: in the liver and spleen without
histological abnormalities
pMWNT: lung accumulation and induced
dyspnea, hunched posture and piloerection
persisting 24 h post-inj. at high dose
[58]
- Pristine MWNTs (pMWNT)
- Low-degree of oxidation
(o-MWNT)
- High-degree of oxidation
(O-MWNT)
Pristine:
L: 10 μm
O-MWNT:
L: 500 nm
All MWNTs:
d: 20–30 nm
♂ Swiss mice
Dose: unknown
Until 28 days
post-inj.
pMWNT & o-MWNT: ➚
hepatotoxicity,
➚ inﬂammatory response and ➚
oxidative damage at 7 days all
recovered at 28 days
O-MWNT did not affect biological
measurements
pMWNTs: induced lethargy post-inj. and
inﬂammatory cell inﬁltration in the liver
o-MWNTs and O-MWNT induced slight or
no inﬂammation
[132]
SWNTs - Dispersion in Tween® 80 Puriﬁed
SWNT
L: 2–3 μm
d:10–30 nm
♂ CD-ICR mice
Dose: 40 μg, 200 μg
or 1.0 mg/mouse
Until 3 months
post-inj.
Dose dependent hepatic injury
Dose dependent oxidative damage in
lung and liver
Black aggregates in lung, liver and spleen.
Dose dependent inﬂammatory cell
inﬁltration in the lungs.
No evidence of hepatic or splenic damages.
[133]
- PEGylated and conjugated
with isoliquiritigenin
(ISL-PEG-SWNT)
Dimensions
not given
Wistar rats
Dose: 200 μg/rat
Until 24 h post-inj.
– Vacuole formation in kidney tubules and
myocardiac cells indicating toxicity (could
be associated with ISL only)
[134]
- Resuspended in BSA
(BSA-SWNT)
- Oxidised (o-SWNT)
BSA-SWNT:
L: 0.1–1 μm
d: 0.8–1.2 nm
o-SWNT:
L: 0.5–2 μm
d: 1–2 nm
Sprague-Dawley
rats (244 ± 8 g)
Dose: 0.5 mg/rat
Until 2 weeks
post-inj.
Normal steatosis/cirrhosis, fatty acid
metabolism, oxidative stress or
transport gene expression in the liver
All SWNTs found in the liver, spleen,
and lung 1 day post-inj.
SWNTs were cleared after 14 days.
[135]
- Non-covalent
functionalisation with
PEGylated phospholipids
(PL-PEG-SWNT)
SWNT
L = 100 nm
BALB/c mice
Dose:
100 μg/mouse
Until 3 months
post-inj.
Normal liver and kidney function PL-PEG-SWNTs accumulated in liver and
spleen. No abnormal histology observed in
these tissues
[136]
-Non-covalently PEGylated
(PEG-SWNT)
- Covalently functionalised
(PEG-o-SWNT)
PEG-SWNT:
L:
100–300 μm
d: 1–5 nm
PEG-o-SWNT:
L: 50–200 nm
d: 1–5 nm
Nude mice
Dose:
0.1 μmol/mouse
12 weeks post-inj.
No signiﬁcant alteration of red blood
cell and neutrophil counts
Presence of brown pigment in liver
macrophages and in the spleen
No alteration of organ and cell morphology
but SWNTs still found in tissues
after 4 months
[128]
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pendent mechanisms (needle-like crossing) constitutes a major advan-
tage compared to other nanocarriers. In addition to the intrinsic ability
to cross biological membranes, CNTs possess high surface area, which
enables the loading and delivery of high doses of drugs to the therapeu-
tic site, aswell as intrinsic optical and thermal properties, with potential
multimodal real-time tracking and photo-thermal applications. Al-
though CNTs display optimal characteristics for use as nanocarriers in
brain delivery, the intrinsic barrier-crossing capacity constitutes a limi-
tation, due to unspeciﬁc bioaccumulation, and therefore speciﬁc brain
target is important to increase brain accumulation and reduce systemic
side effects.
5.1. Intracranial administration of CNT-based therapeutics
Local administration of therapeutics could bypass the BBB restriction
and allow effective therapeutic doses to be achieved in the diseased tis-
sues. This approach could be relevant in certain brain disorders, such as
tumours and stroke, in which initial surgical approach is often neces-
sary. Scheme 1 highlights themain strategies involving local CNT-medi-
ated therapeutic brain delivery.
The conjugation of immunostimulatory CpG oligonucleotides to
SWNTs was shown by Zhao and collaborators to be beneﬁcial for the
treatment of glioma-bearing mice [137]. Increased uptake of SWNT-
CpG by tumour-associated inﬂammatory cells was found after a single
intracranial injection (compared to the free CpG), which resulted in a
strong anti-tumoural response, decreased tumour size and an increase
in median animal survival time [137].
Taking advantage of the capacity of CNTs to absorb NIR radiation and
convert it to heat, Santos and colleagues used CNTs for photothermal-
mediated brain tumour therapy. The authors showed that a combina-
tion of intratumoural SWNT injection and NIR exposure in athymic
GBM-bearing mice not only suppressed tumour growth compared to
SWNTs or NIR per se, but also inhibited tumour recurrence for up to
80 days [138]. The electrical properties of CNTs prompted several re-
search groups to use these carriers as scaffold for stem-cell mediatedScheme 1. Different stereotactically-deliveredneuronal repair. Studies by Moon and colleagues in rats with stroke-in-
duced brain injury revealed that focal injection of neural progenitor cell
(NPC)-impregnated CNTs improved rat behaviour and reduced infarct
cyst volume and area [139]. Similarly, pre-injection of amine-
functionalised SWNTs onto the right lateral ventricle was shown to re-
duce the infarction area and improve behavioural functions following
focal ischemic injury in rats [140]. The authors showed that the neuro-
protective effect was achieved by reducing apoptosis, inﬂammation
and glia activation and proposed that, even without NPCs, the high sur-
face energy of the positively-charged SWNTs provided a favourable en-
vironment for neuronal regeneration. In a very recent study by Xue and
colleagues, intraventricularly-injected aggregated SWNTs (aSWNTs)
were shown to reducemethamphetamine (METH) addiction symptoms
in mice by causing oxidation of METH-enhanced extracellular dopa-
mine, which induced inhibition of the rewarding and psychomotor-
stimulating effects of METH [141].
A previous study from our group revealed that the local f-MWNT-
mediated delivery of siRNAs targeting caspase-3 (siCas3) successfully
prevented neuronal death in an endothelin-1 (ET-1) rat stroke model
(Fig. 5) [142]. This was supported by observation of a decrease in apo-
ptosis in the penumbra lesion (Fig. 5A–C) and a statistically signiﬁcant
improvement in the “skilled reaching” behaviour test (Fig. 5D) for f-
CNT:siCas3 treated rats, compared to animals receiving complexes of
non-speciﬁc siRNA (siNEG) and f-CNT (f-CNT:siNEG) or siCas3 alone.
While the intracranial delivery of drugs could be of clinical utility, its
wide application is nevertheless limited by the invasiveness of the tech-
nique and patient compliance. The versatility of nanotubes and their
unique mechanism of interaction with cells paved the way for re-
searchers to explore the use of CNTs as carriers for systemic drug deliv-
ery to the brain.
5.2. Systemic administration of CNT-based therapeutics
The ability of CNTs to penetrate biological membranes without
perturbing the membrane integrity prompted researchers to test CNTs
as vehicles for systemic therapeutic delivery across the BBB. EarlyCNT-based strategies for brain therapy.
Fig. 5. In vivo uptake and degradation of f-MWNTs by microglia after intracranial administration into mouse brain. (A–D) TEM images of brain sections showingmicroglia cells engulﬁng
MWNT-NH3+ within phagosomes 48 h after injection (red squares). (B, D) High magniﬁcation TEM images showing clear loss of tubular structure of MWNT-NH3+ in some phagosomes of
themicroglia (shown inD) evenwithin 48h post-administration (adapted from [76]). (E–H)RNAi using f-CNT in vivo. (E) Dosage regimen of the siRNAand endothelin (ET-1) into C57Bl/6
mice and (F) TUNEL staining of the mouse brain cortex after injection of 5% dextrose, f-CNT alone, siCaspase3 alone, and the siCaspase3:f-CNT complexes, followed by ET-1 injection. (G)
The f-CNT:siCaspase3 group showed the least apoptosis quantitatively indicating effective and speciﬁc siRNAdelivery in vivo compared to siRNAalone. (H) Behavioural analysis of rats after
stroke induction in all the treated groups using the skilled reaching test (adapted from [142]).
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in primary brain endothelial cells [143–145] and other commonly used
in vitro BBB models [146].
5.2.1. In vitro BBB translocation
The interaction of f-MWNTswith the BBB has been previously inves-
tigated by our group using a BBB co-culture model comprised ofprimary porcine brain endothelial cells (PBEC) and primary rat astro-
cytes. This model replicates the physiological and biochemical features
of the human BBB, including high trans-endothelial electric resistance
(TEER), expression of membrane transporters and tight junction pro-
teins [143]. TEM analysis revealed that f-MWNTs were quickly
internalised (within 4 h) by PBEC cells via endocytosis, with f-MWNTs
being released from endocytic vesicles near the abluminal side of
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showed that this process did not cause any damage to the cell mem-
brane (Fig. 6). Since no involvement of the tight junctions was detected
during translocation, it was suggested that f-MWNTs use a transcellular
route to cross the BBB.
In a subsequent study, the effect of CNT diameter on BBB transloca-
tion was investigated. Gamma counting was used to quantify the rate
of translocation of “wide” (~35.9 nm diameter) (w-MWNTs) or “thin”
(~9.2 nm) (t-MWNTs) f-MWNTs across the PBEC co-culture model over
a 72 h period. In general, higher percentage transport across PBEC was
achieved for w-MWNTs compared with t-MWNTs (~15.6% and 7.6% ofFig. 6. Transcytosis of f-MWNTs across an in vitro BBBmodel. PBEC were incubated withMWNT
processing for imaging. (A) Bright ﬁeld TEM and (B) low voltage STEM images of polyester ﬁlter
MWNTs-NH3+ clusters are seen interacting with the PBECmonolayer (or already within vesicles
partly opened towards the basal chamber to allow the release of vesicle contents. Scale bars: (A
dark ﬁeld; HAADF: high angular annular dark ﬁeld. Figure reproduced from [144].total dose after 72 h, respectively) [145]. Targeting of f-MWNTs was
also tested in this study, in order to assess whether BBB translocation
could be further improved. For this purpose, CNT synthesis was modi-
ﬁed to incorporate a targeting peptide, angiopep-1 (ANG), to the carri-
er surface. This small peptide binds LRP1, a lipoprotein receptor that is
overexpressed on brain endothelial cells of the BBB and several
human tumours [147]. Indeed, higher values were obtained for ANG-
functionalisedw-MWNT and t-MWNTs (~20.3% and 11.6%, respective-
ly) compared to the non-targeted carrier (~15.6% and 7.6%) [145],
using the in vitro PBEC co-culture model. This conﬁrmed that conjuga-
tion of this small LRP1-targeting peptide to f-CNT, enhances BBBs-NH3+ (20 μg/ml) for 4, 24 or 48 h. Cells were ﬁxed in 2.5% glutaraldehyde for 24 h, before
s showing the uptake and transcytosis ofMWNTs-NH3+ across the PBECmonolayer. At 4 h,
), while at 24 h the clusters appear within endocytic vesicles. At 48 h, the vesicles are seen
) 1 μm; inset: 500 nm. (B) 4 and 24 h: 500 nm; 48 h: 400 nm. BF: bright ﬁeld; ADF: annular
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targeted therapies.
The capacity of CNTs to cross the BBB in vitrowithout compromising
this barrierwas also demonstrated by Shityakov and colleagues. The au-
thors used phase-contrast and ﬂuorescence microscopy in combination
with molecular dynamics simulation to demonstrate that amine-
functionalised FITC-labelled MWNTs (MWCNT–NH3+–FITC) were able
to penetrate murine microvascular cerebral endothelial (cEND) mono-
layers over a 48 h period, without compromising cell integrity [146].
5.2.2. In vivo BBB crossing
In addition to several in vitro studies, pre-clinical studies involving
i.v. injection of CNTs provided unequivocal evidence of the capacity of
CNTs to reach the tissues beyond the BBB.
In one of our veryﬁrst studies, aiming at determining the impact of f-
MWNT diameter on systemic organ biodistribution, it was revealed thatFig. 7. Uptake of radiolabelled f-MWNTs into murine brain after systemic administration. C57
(50 μg, 0.5 MBq). After perfusion with heparin-containing saline, brain accumulation was q
30 min, 1 h, 4 h and 24 h. The overall brain uptake of nontargeted and targeted (ANG-conju
(%ID/g), revealed higher uptake for t-MWNTs. The radioactivity of (D) t-MWNTs or (D) w-MW
calculate the brain parenchyma/blood ratios. *p b 0.05; **p b 0.01.
Adapted from [145].radiolabelled t-MWNT conjugated to humanised IgG or fragment anti-
gen binding region (Fab′) showed higher tissue afﬁnity (including
higher brain afﬁnity) compared to w-MWNTs [148]. In a subsequent
study, designed to investigate in detail the brain uptake, accumulation
and elimination of t- and w-MWNTs (with or without ANG conjuga-
tion), following systemic administration in healthy mice [145], higher
brain uptake was also found for t-MWNT (~2.6% ID/g tissue at 5 min)
compared to w-MWNT (~1.1%) (Fig. 7). Importantly, ANG brain
targeting effect was signiﬁcant for w-MWNT-ANG (~2.0% vs 1.1%) but
not for t-MWNT-ANG (~3.0% vs 2.6%). The capillary depletion method
(which removes the vascular fraction of the brain), was then used to
evaluate the f-MWNT content in the parenchyma and vascular brain
fractions. Greater parenchyma uptake/accumulation was found for t-
MWNTs compared to w-MWNTs, particularly at early times post-injec-
tion,while better parenchyma retentionwas found forw-MWNT conju-
gates. Negative elimination rate constants (Kel), indicating parenchymaBL/6 mice were injected, via tail vein, with wide (w-MWNT) or thin (t-MWNT) MWNTs
uantiﬁed by gamma scintigraphy, which was followed by capillary depletion at 5 min,
gated) (A) t-MWNTs or (B) w-MWNTs, expressed as % injected dose per gram of brain
NTs in brain parenchyma and capillaries, measured after capillary depletion, was used to
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(Kel ~−0.026 and−0.05, respectively), compared to t-MWNT and t-
MWNT-ANG which exhibited positive Kel values (~ 0.034 and ~0.019)
suggesting elimination from parenchyma.
Since LRP1 overexpression has been described not only on brain en-
dothelial cells but also for malignant brain tumours [147], experiments
were also performed to investigate the capacity of i.v. injected ANG-
coupled w-MWNTs, which show higher brain parenchyma retention,
to target this type of tumour. Interestingly, w-MWNT-ANG not only
showed signiﬁcantly higher uptake in glioma when compared to nor-
mal brain, but also enhanced accumulation in glioma compared to the
passively targeted w-MWNT [145], which suggests that ANG-coupling
can provide a double-targeting effect, with improved brain and tumour
uptake.
Overall, although in vitro data suggested that wider f-MWNTs are
more efﬁcient in crossing the BBB, the available in vivo data suggests
that uptake in healthy brain tissues after systemic injection is favoured
by f-MWNTswith smaller diameter, while wider MWNT exhibits better
brain retention. ANG conjugation enhances brain uptake of wider
MWNTs but offers no advantage to brain uptake of thinner ones. ANG-
modiﬁed f-MWNT, of wider diameter, seems to be the most suitable
candidate among the ones studied, for BBB and brain tumour double-
targeting. Since the BBB-crossing studies were performed with
“empty” CNTs, nevertheless, it is not known whether the % ID achieved
is sufﬁcient to generate a disease-speciﬁc response.
5.2.3. In vivo brain distribution
Following the encouraging results where f-MWNT achieved reason-
ably high brain parenchyma accumulationwhen delivered systemically,
we usedmulti-modal imaging techniques to study inmore detail the ki-
netics and spatial distribution of i.v. injected f-MWNTs in the brain
[149]. SPECT/CT imaging clearly showed accumulation of radiolabelled
t-MWNTs over the entire brain at the early time points after injection
(5 min and 30 min), with higher radioactivity being detected in the
mid-brain region (Fig. 8A). Autoradiography of brain slices (2 mm
thick), which allows greater spatial resolution via increased exposure
times and support of semi-quantitative analysis, provided further evi-
dence of the preferential accumulation in the mid-brain region. Higher
intensity was detected in sections of mid-brain (sections c3–5), while
relatively lower radioactivity was detected in brain cortex (Fig. 8B).Fig. 8. Brain imaging after systemic administration of radiolabelled Fab′-conjugated t-MWNT
reconstructed SPECT/CT images of mouse brains at 0–30 min, 4 h and 24 h post injection (0
injection (5–7 MBq) and 2 mm thick sections were prepared by coronal sectioning (from olfac
Adapted from [149].Importantly, gamma counting and TEM (Fig. 9A) showed preferential
location of t-MWNTs in the brain capillaries up to 24 h after injection,
which indicates that the MWNTs enter the brain via its endothelium.
Moreover, TEM images showed that brain capillaries remained intact
and circular, thus indicating that t-MWNT uptake into the brain was
not caused by inﬂammation or the damage to the BBB.
Taking advantage of its inherent optical properties, t-MWNTs were
also directly imaged in brain sections and whole brain using state-of-
the-art techniques, namely Raman andmulti-photon luminescence mi-
croscopy (Fig. 9B). The typical D (1309 cm−1) and G (1599 cm−1)
MWNT Raman bands were seen in the spectra of capillaries (as well as
in control bulk material), while no bands could be detected in whole
brain sections. It is worth noting that t-MWNT accumulation in capil-
laries was ~4-fold higher than brain parenchyma. This highlights the
limitation of this technique in terms of poor sensitivity.
5.2.4. In vivo brain-targeted therapy
While the above-mentioned studies investigated the BBB interac-
tion, translocation and brain distribution of f-CNTs in vivo, they involved
“empty” carriers. To date, very few studies investigated the delivery of
CNT-formulated drugs to the brain following systemic administration.
Yang and colleagues used SWNTs for brain delivery of acetylcholine
(ACh) to Alzheimer disease (AD)-bearing mice. In this regard, the ad-
ministration of SWNTs-Ach, via oral gavage, resulted in improved learn-
ing and memory capabilities 8 h after treatment. Contrasting results
were obtained in animals treated with empty SWNTs or the free Ach,
in which no signiﬁcant improvement was observed [150]. This study
also highlighted the importance of the correct dosing of CNTs in brain-
targeted therapies, as the mitochondria were shown to be affected by
high concentrations of SWNTs. In a study by Ren and collaborators,
PEGylated and carboxylated MWNTs (oxMWNT-PEG) modiﬁed with
ANG were used as carrier to deliver doxorubicin to mouse brain. In ad-
dition to increased brain uptake of Dox-oxMWNT-PEG-ANG compared
to Dox-oxMWNT-PEG or Dox per se after 1 to 6 h, the authors observed
a substantial increase in survival of glioma-bearing animals treatedwith
Dox-oxMWNT-PEG-ANG, compared to the saline-treated group [151].
Since ﬂuorescence non-quantitative imaging was used to evaluate the
doxorubicin dispersion in the brain, the accumulation rate of Dox-
oxMWNT-PEG-ANG could not be compared to other delivery systems.
Intravenously-injected NIR-ﬂuorescent PEG-conjugated SWNT sensors,s. C57BL/6 mice were administered 50 μg/ml of [111In]MWNT-Fab′ via tail vein. (A) 3D
.5 MBq). (B) For autoradiography, brains were harvested at 5 min, 4 h or 24 h after i.v.
tory bulbs to brainstem). Sections were then analysed by autoradiography.
Fig. 9. Label-free brain imaging after systemic injection of Fab′-conjugated t-MWNTs. C57BL/6micewere injected i.v. withMWNT-Fab′-DTPA (200 μg). (A) 5min after injectionmicewere
perfused with 2.5% glutaraldehyde (in 0.1 M cacodylate buffer), the brains were isolated and kept for another 24 h in ﬁxation solution, before processing for TEM imaging. MWNT-Fab′-
DTPA clusters are shown in the three different panels, including under higher magniﬁcation and enhanced contrast (middle panel, rectangular inlet). (B) For lifetime microscopy, the
brains were isolated 1 h after injection (following perfusion with DiI and 4% PFA) and subsequently sectioned into 1 mm thick slices. Lifetime measurements are displayed below the
multiphoton images (C, DiI; D, MWNT-Fab′-DTPA; E, position where both were present). Scale bar: 50 μm.
Adapted from [149].
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local nitric oxide concentration in the brain, with a detection limit of
1 μM, with potential applications in sensing and therapy [152].
Table 3 summarizes the main studies involving local and systemic
administration of CNT-based carriers for brain delivery, including carri-
er modiﬁcations, disease model and stage of development.
5.3. In vivo toxicity of CNTs in brain tissues
Cell andmacromolecule trafﬁc into the brain is strictly controlled by
a tight BBB, efﬂux transporters and the presence of immune cells(microglia), to ensure a proper microenvironment in which neurons
can function. Exposure to CNTs could disturb this fragile balance and re-
sult in cytotoxicity. No studies have yet assessed brain toxicity following
systemic administration of CNTs. The evidence available, obtained from
studies involving intracranial injection of nanotubes, suggests that sur-
face functionalisation contributes to the cytotoxic outcome.
In a study by Bardi and colleagues, neuron toxicity was not detected
in mouse brain cortex after stereotactic micro-injection of Pluronic®
F-127 coated-MWNTs (MWNT:F127). Histological examination revealed
small neuronal damaged near the injection site (due to the mechanical
penetration of the brain) but no further damage was observed after
Table 3
Representative studies involving local or systemic administration of CNT-based nanocarriers for brain delivery.
List of abbreviations in this table: TMZ: temozolomide; SWNTs: single-walled carbon nanotubes; MWNTs: multi-walled carbon nanotubes; Ox-SWNT/MWNT: oxidised SWNT/MWNT;
NIR: near infrared; NPCs: neural precursor cells; aSWNTs: aggregated SWNTs; METH: methamphetamine; NH3+-MWNTs: ammonium functionalized MWNTs; BBB: blood-brain barrier;
Fab: fragment antigen binding region; ANG: angiopep1; w-MWNT: wide MWNT; t-MWNT: thin MWNT; AD: Alzheimer's disease; DOX: doxorubicin; NO: nitric oxide.
CNT type and
functionalisation
Therapeutic
approach
Pre-clinical setting
or disease model Dosage Main ﬁndings Reference
Local
administration
SWNT-PEG Glioma
immunotherapy -
conjugation with CpG
oligonucleotides
GL261 mouse
glioma
Single intracranial injection (2.5 μg
CNT/5 μg CpG)
Strong anti-tumoural response,
decreased tumour size, increased
median animal survival
[137]
Ox-SWNT Photothermal
anti-glioma therapy
U251
TMZ-resistant
mouse glioma
Single intratumoural injection
(3 μg/ml) + single NIR laser treatment
(10 min, 6.75 W/cm2)
Suppression of tumour growth
and inhibition of tumour
recurrence for up to 80 days
[138]
Commercially
acquired CNTs
Stroke treatment -
conjugation to neural
precursor cells
Rat focal cerebral
ischaemia (arterial
occlusion)
Microinjection on the stroke area
(striatum) of CNTs impregnated with
5 × 105 NPCs
Improved rat behaviour in
neurological tests and reduced
infarct cyst volume and area
[139]
Ox-SWNTs Stroke treatment Rat focal cerebral
ischaemia (arterial
occlusion)
Pre-injection of 0.04 μg SWNTs onto the
right lateral ventricle injection
Reduction in infarction area and
improvement in behavioural
functions
[140]
NH3+-MWNTs Stroke treatment -
siRNA-mediated
Caspase3 silencing
Mice and rat
endothelin stroke
model
Single intra-cortical injection of 0.5 μg
NH3+-MWNTs
Decrease in apoptosis on the
lesion area and improvement in
behaviour tests
[142]
a-SWNTs METH addiction Mouse model of
METH
self-administration
Pre-injection via cannula implanted on
lateral ventricle, 1–2 μg SWNTs
Reduction in the rewarding and
psycho-motor enhancing effects
of METH
[141]
Systemic
administration
MWNTs BBB crossing studies -
conjugation to
IgG/Fab
Normal healthy
mouse brain
“wide” (w) or “thin” (t) MWNTs,
50 μg injected via tail vein,
Higher brain afﬁnity for t-MWNT
compared to w-MWNT
[148]
MWNTs BBB crossing studies -
conjugation to ANG
Normal healthy
mouse brain and
GL261 mouse
glioma
t-MWNT/w-MWNT, 50 μg injected via
tail vein
Higher brain uptake found for
t-MWNTs (~2.6% ID/g tissue at
5 min) compared to w-MWNTs
(~1.1%);
Higher brain retention of
w-MWNTs compared to
t-MWNTs;
Higher glioma uptake found for
w-MWNTs-ANG
[145]
Ox-MWNTs Kinetics and
distribution of CNTs
in brain - conjugation
to Fab
Normal healthy
mouse brain
50 μg injected via tail vein Accumulation of CNTs over entire
brain early after injection, with
preferential accumulation in the
midbrain region
[149]
SWNTs Alzheimer's disease
(AD) therapy -
conjugation with
acetylcholine (Ach)
Mouse model of
AD (injection of
kainic acid)
SWNT-Ach (25 mg/kg) administered by
gastrogavage 24 h before injection of
kainic acid
Improved learning and memory
capabilities 8 h after treatment
[150]
Ox-MWNT-PEG Glioma
chemotherapy –
conjugation to ANG
and DOX
C6 mouse glioma
model
Dox-MWNT-PEG-ANG (1.5 mg
DOX/0.375 mg MWNT) injected via tail
vein at 2nd, 5th, 8th and 11th days after
tumour implantation
Signiﬁcant increase in animal
survival
[151]
SWNT-PEG-polymer Biosensors for NO
detection –
conjugation to
alginate
Normal healthy
mouse brain
50 μg of alginate-encapsulated
SWNT-PEG injected via tail vein
Selective detection of NO in the
brain, with a detection limit of
1 μM
[152]
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that cortical stereotactic injection in mouse brain of MWNTs
functionalised by 1,3-dipolar cycloaddition (MWNTs-NH3+) resulted in
lower inﬂammation compared to the oxidised carrier (ox-MWNTs-
NH3+) [154]. Similar uptake levels of the compoundswere found in astro-
cytes, microglia and neurons, but a signiﬁcantly higher release of the
pro-inﬂammatory cytokines TNF-α and IL-1β, as well as microglia acti-
vation, was detected after injection of ox-MWNTs-NH3+ compared to
MWNTs-NH3+. A recent follow-up study revealed that microglia is in-
volved in the cytotoxic response generated by ox-MWNTs in brain tis-
sue. Exposure of ox-MWNTs to neuronal cultures did not lead to
detectable cytotoxicity (measured by themodiﬁed LDH assay), whereas
signiﬁcant cytotoxicity was found in mixed glial cultures isolated from
striatum, but not from the frontal cortex. Striatum-derived mixedcultures contain a higher density of microglia, compared to the higher
amount of astrocytes in the frontal cortex, thus suggesting thatmicroglia
is responsible for the CNTs-induced cytotoxicity in brain tissue [155].
5.4. Biodegradation of CNTs in brain tissues
The biodegradation of CNTs by brain cells has been studied in vitro
and in vivo. Strong evidence suggests that CNTs can be degraded within
human brain tissue by human MPO and hydrogen peroxide (H2O2).
Using Raman spectroscopy, Kagan and colleagues demonstrated
that, in the presence of H2O2, MPO promoted SWNT biodegradation
via generation of reactive hypochlorite radical intermediate species
that oxidise parts of the CNT wall-structure [74]. Importantly, the
presence of PEG (widely used to increase in vivo bioavailability) did
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coated SWNTs (SWNTs-PEG) was observed after incubation for
7 days with MPO, H2O2 and NaCl. Further testing, carried out ex
vivo using human neutrophils (which secrete MPO along with
other proteases) showed efﬁcient SWNTs-PEG degradation after
only 8 h [74]. In a follow-up study, the biodegradation of SWNTs-
PEG was proposed to occur in a two-step process, with the initial
stripping of the PEG coating, mediated by secreted proteases, follow-
ed by SWNT degradation via surface defects [156]. Interestingly, PEG
removal from the surface of SWNTs-PEG after systemic administra-
tion in mice has been previously described, but no explanation was
provided for the mechanism [157].
In vivo data provides further evidence of the role of MPO on the CNT
degradation in brain cells. Increased inﬂammation and lower SWNT
clearance rate were detected in MPO mouse knockouts following pha-
ryngeal aspiration, compared to wild type animals [75]. An elegant
study by Nunes and colleagues, which used electron microscopy to as-
sess degradation of stereotactically-administered f-MWNTs in mouse
brain cortex, detected loss of cylindrical structure of f-MWNTs following
internalisation into microglia [76]. The oxidative environment of the
microglia, which contains MPO, peroxidases and other degradative en-
zymes, could be involved in the observed degradation.
Overall, the high surface area of CNTs, intrinsic capacity to cross the
BBB, controlled toxicity and degradability in the presence of MPO en-
zymes are encouraging properties/observations for future applications
of CNTs in the brain.6. Concluding remarks and future perspectives
The progress achieved on the synthesis, design and functionalisation
of carbon nanotubes has greatly contributed for the promising results
obtained in in vitro and in vivo CNT-related studies. Surface modiﬁca-
tions have improved carrier biocompatibility and targeting,while short-
ening CNT length improved pharmacokinetics and organ distribution. A
wide range of in vitro studies has also revealed the mechanisms by
which CNTs can lead to cell toxicity, including oxidative stress andmito-
chondrial dysfunction. Although a few studies have addressed the long-
termbiocompatibility and the effects of CNTaccumulation in the human
organs (namely the effects of pulmonary exposure) a higher number of
long-term follow-up studies should aim at evaluating the long-term
pharmacokinetics, organ accumulation, intracellular fate and possible
cytotoxicity of intravenously-injected CNTs. The results of these studies
will provide essential information about the behaviour of CNTs in com-
plex physiological environment, allow the reﬁnement of physicochem-
ical and biocompatible properties and, ultimately, lead to the
development of clinically-ready nanotube-based carriers. While re-
search involving CNT-mediated therapeutic delivery to the brain has
shown that biocompatible CNTs can efﬁciently reach the brain, little in-
formation is available about the amount of therapeuticmolecule needed
to obtain a signiﬁcant therapeutic beneﬁt. Futurework should therefore
focus on determining effective therapeutic disease-speciﬁc dosage, im-
proving brain delivery and clarifying the fate of CNTs with the different
CNS tissues, in healthy and diseased brain. This information would be
extremely helpful for the design/production of improved f-CNT-based
delivery systems that can, in the future, constitute primary options for
efﬁcient targeted brain therapy.Acknowledgments
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